ArticleFrontiers in endocrinology2025
Study of the predictive value of testosterone in androgen deprivation therapy for metastatic hormone-sensitive prostate cancer-the dual clinical research center for western and eastern China.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the association between early testosterone (T) response to androgen deprivation therapy (ADT) and clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Methods: This retrospective cohort study analyzed 366 mHSPC patients treated at The People's Hospital Bozhou and The First Affiliated Hospital of Xinjiang Medical University. The participants were stratified by 1-month testosterone response: response group (T < 50 ng/dL) and non-response group (T > 50 ng/dL). The response group was further subdivided into ultra-low (T < 20 ng/dL) and low (20-50 ng/dL) response groups. Comparative analyses of baseline characteristics, progression to metastatic castration-resistant prostate cancer (mCRPC), and survival outcomes were carried out. Results: No significant intergroup differences were observed in Gleason score, tumor stage, prostate volume, initial PSA, PSA density, perineural invasion, visceral metastasis, or hazard level (all Conclusion: Ultra-low T levels (<20 ng/dL) after 1-month ADT can be used as a reference standard for predicting survival outcomes and may guide treatment optimization in mHSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.